A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 124 participants.

Also called NCT02331680

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 124 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02331680
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02331680. Randomized; double masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2016-05 (actual). Results posted on 2019-10-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration
Condition
Chronic Renal Failure
Intervention (Drug)
OPC-41061
Intervention (Drug)
OPC-41061
Intervention (Drug)
Placebo
Lead sponsor
Otsuka Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02331680
Content hash
1d1cf88b18dc5bdf92f8c862686398aca46eafd8bd442432f96881edfd1d6a8f